Efgartigimod alfa
Efgartigimod Alfa
Efgartigimod Alfa (pronounced as ef-gar-ti-gi-mod al-fa) is a pharmaceutical drug designed for the treatment of autoimmune diseases.
Etymology
The name "Efgartigimod" is derived from the drug's mechanism of action. "Ef" stands for effector function, "garti" is an abbreviation for neonatal Fc receptor (FcRn) antagonist, and "mod" signifies modulator. "Alfa" is a common suffix used in biopharmaceutical naming to denote the first in a series or class.
Mechanism of Action
Efgartigimod Alfa works by targeting the neonatal Fc receptor (FcRn), which is responsible for preserving Immunoglobulin G (IgG) antibodies in the body. By blocking this receptor, the drug reduces the levels of harmful IgG antibodies, which are often elevated in autoimmune diseases.
Clinical Uses
Efgartigimod Alfa is primarily used in the treatment of Myasthenia Gravis, a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles. It is also being investigated for potential use in other autoimmune diseases, such as Immune Thrombocytopenia and Pemphigus Vulgaris.
Related Terms
- Autoimmune Disease
- Immunoglobulin G (IgG)
- Neonatal Fc receptor (FcRn)
- Myasthenia Gravis
- Immune Thrombocytopenia
- Pemphigus Vulgaris
External links
- Medical encyclopedia article on Efgartigimod alfa
- Wikipedia's article - Efgartigimod alfa
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski